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1. INTRODUCTION {#ajt15004-sec-0001}
===============

Liver transplantation saves lives in liver failure and hepatocellular carcinoma and, in the context of an ever‐increasing demand for transplantation, promoting equality of access has become a focus.[1](#ajt15004-bib-0001){ref-type="ref"}, [2](#ajt15004-bib-0002){ref-type="ref"}, [3](#ajt15004-bib-0003){ref-type="ref"}, [4](#ajt15004-bib-0004){ref-type="ref"} Recent reports from the United States have described worsened outcomes for liver transplantation for those living at greater distances or travel times from transplant centers; the effect is seen prior to listing, from listing, and from the point of transplantation.[5](#ajt15004-bib-0005){ref-type="ref"}, [6](#ajt15004-bib-0006){ref-type="ref"} Such worsened outcomes are also reported for the transplantation of other solid organs[7](#ajt15004-bib-0007){ref-type="ref"} and for treatment of cancer for those living at greater distances from specialist cancer care centers.[8](#ajt15004-bib-0008){ref-type="ref"} Conversely, improved outcomes are reported for centralization of services for certain specialist procedures (eg, surgery for pancreatic cancer in the United Kingdom, and for liver transplantation in the United States).[9](#ajt15004-bib-0009){ref-type="ref"}, [10](#ajt15004-bib-0010){ref-type="ref"}

The United Kingdom National Health Service (UK NHS) has a well‐established liver transplant program, and represents the only option for liver transplantation within the United Kingdom. Since 1992, the NHS provision of care has been split between 7 centers. Recent analyses of the provision of national liver transplant services have emphasized reducing disparity and considering the building of new transplant center(s) to do so.[11](#ajt15004-bib-0011){ref-type="ref"}, [12](#ajt15004-bib-0012){ref-type="ref"}, [13](#ajt15004-bib-0013){ref-type="ref"}, [14](#ajt15004-bib-0014){ref-type="ref"} In addition to potential effects on patient outcome, it is reported that proximity to treating transplant center is identified as a factor important to many liver transplant patients.[15](#ajt15004-bib-0015){ref-type="ref"} To date, however, the roles of distance and travel time in UK liver transplantation have not been formally assessed.

In this analysis, we sought to describe the geographic distribution of UK patients using liver transplantation services, assess whether current variations in travel time are associated with differences in outcome, and to assess where a potential new liver transplant center might be best placed to minimize travel time.

2. MATERIALS AND METHODS {#ajt15004-sec-0002}
========================

The NHS Blood and Transplant national registry was queried for all patients ≥18 years old listed for liver transplantation in the United Kingdom from 1995 to 2014 inclusive; approval for the study was given by the UK Transplant Registry. Patients listed for repeat transplants, those listed on a "super‐urgent" basis, those listed for simultaneous multi‐organ transplantation, and those listed from postal codes (postcodes) outside England, Scotland, or Wales were excluded (Figure [1](#ajt15004-fig-0001){ref-type="fig"}). Those resident in Northern Ireland were excluded because of the incomplete availability of Census data, incomplete availability of data on population liver‐related mortality, and the distorting effects of air travel. Data sources are summarized in Table [S1](#ajt15004-sup-0010){ref-type="supplementary-material"}.

![Flowchart of exclusions. Adult patients (17 186) were listed for liver transplantation from 1995 to 2014 inclusive. After application of the exclusion criteria, an analysis cohort of 11 188 was generated](AJT-19-208-g001){#ajt15004-fig-0001}

To preserve anonymity, only the first portion of each patient's postcode was available describing the "postcode district." The longitude and latitude for the centroid of each of 2736 postcode districts (Figure [S1](#ajt15004-sup-0001){ref-type="supplementary-material"}) and the precise location of each renal or liver transplant center was then entered into the Google Maps API (Alphabet, Palo Alto, CA). The shortest driving distance and travel time, unadjusted for traffic conditions, were then calculated from each postcode district to each transplant center. Centers with a preexisting renal transplant center were chosen as a proxy for the presence of sufficient infrastructure to support a new liver transplant center. Travel times were divided into 3 groups: \<60 minutes, 60‐119 minutes, and \>119 minutes. Population estimates for postcode districts were obtained from the 2011 UK National Census; adjusted standardized mortality ratio (ASMR) estimates for liver disease were obtained for 2011 from national agencies. Geographic boundaries of the organizational subunits for which ASMR was available were overlaid with postcode districts and each postcode district was assigned the ASMR for the healthcare administrative area with the most shared area. Mapping was performed using Quantum GIS v2.18.7 (<https://qgis.osgeo.org>).

For the assessment of outcome from listing, death on the waiting list and de‐listing for worsening condition were treated as outcomes, with patients censored if they received a transplant or were de‐listed because of an improvement in their condition. For the assessment of outcome from transplantation, retransplant‐free survival was assessed. Here, the outcomes of interest were mortality and the receipt of a second transplant, with patients censored at the end of follow‐up. Assessments were performed with both travel time and travel distance as both categorical and continuous variables. Primary liver diagnoses were categorized into the following categories: primary biliary cholangitis, autoimmune hepatitis, hepatitis B virus, primary sclerosing cholangitis, alcohol, hepatitis C virus, nonalcoholic fatty liver disease, or other. The presence or absence of hepatocellular carcinoma was coded separately from primary diagnosis. Those patients with missing data in 1 or more categories were excluded from the univariable analyses in question and entirely from multivariable analyses.

Univariable analyses were used to compare differences between the 3 travel time categories: the nptrend test in Stata for continuous variables,[16](#ajt15004-bib-0016){ref-type="ref"} the Mann‐Whitney *U* test to compare travel time between 2 categorical variables, and the Kruskal‐Wallis test to compare 3 or more categorical variables. To assess for outlying contributors of listings for liver transplantation, the relative contribution of different postcode areas---each including multiple postcode districts---to listings for liver transplantation, rates, and confidence intervals were calculated to generate a funnel plot according to the method of Spiegelhalter.[17](#ajt15004-bib-0017){ref-type="ref"}

To assess outcome from the point of listing for transplantation, competing‐risks regression models according to the method of Fine and Gray were constructed.[18](#ajt15004-bib-0018){ref-type="ref"} Analyses were constructed both with death as the primary outcome and transplantation or recovery as a competing risk, and also with attaining transplantation or recovery as a primary outcome and death or all other outcomes as a competing risk. To assess outcome following liver transplantation, a Cox proportional hazards model was constructed with the incidence of either death (of any cause) or retransplantation considered a failure.

In both competing risk and Cox models, variables other than travel time were selected for inclusion in the final model with a backwards stepwise approach with a cut‐off of *P* \< .1. Visual inspection was used to ensure no crossover of Kaplan‐Meier survival plots for each categorical value. For Fine‐Gray competing risk models, cumulative sums of residuals were used to confirm the appropriateness of the model constructed for each variable; for Cox models, Martingale and Cox‐Snell residuals were calculated.[19](#ajt15004-bib-0019){ref-type="ref"} For skewed values with poor fit, logarithmic transforms were used (this was required in 2 instances: intensive treatment unit stay duration and international normalized ratio). A value of *P* \< .05 was assumed to be representative of statistical significance. Statistical analyses were conducted using StataMP v15.0 (StataCorp, College Station, TX) using the University of Birmingham's BlueBEAR High Performance Computing Cluster.

3. RESULTS {#ajt15004-sec-0003}
==========

Adult listings (17 186) for liver transplantation were identified. After exclusions, 11 188 were included in subsequent analysis (Figure [1](#ajt15004-fig-0001){ref-type="fig"}). Data on distance and travel time were available for 11 184 of 11 188 transplants (\>99.9%), with the remainder not having a valid recorded postal code. The median distance to the nearest center was 67.3 km (interquartile range \[IQR\] 23.6‐107.6); median travel time was 60 minutes (IQR 36‐86).

Travel time to nearest transplant center was closely correlated with distance from nearest transplant center (*r* ^2^ = 0.913; *P* \< .001) (Figure [S2](#ajt15004-sup-0002){ref-type="supplementary-material"}). For the remainder of the analysis, travel time was used as the primary comparator. The majority of patients attended their nearest liver transplant center (8505 of 11 184; 76.0%) (Figure [2](#ajt15004-fig-0002){ref-type="fig"}). Those who did not attend their nearest center were primarily resident in areas of near equidistance between centers, or in the northwest or southwest of England (Figure [S3](#ajt15004-sup-0003){ref-type="supplementary-material"}).

![Geographic distribution of listings for liver transplantation. Geographic distribution of patients listed for liver transplantation in England, Scotland, and Wales 1995‐2014 inclusive after the exclusions detailed in Figure [1](#ajt15004-fig-0001){ref-type="fig"} \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJT-19-208-g002){#ajt15004-fig-0002}

Several postcode areas supplied a disproportionate number of total listings as a proportion of the resident population as at the 2011 National Census population (Figure [3](#ajt15004-fig-0003){ref-type="fig"}) at a confidence level of 3 standard deviations (*P* \< .002). Among these were 6 out of 7 postcode areas containing one of the liver transplant centers; the seventh transplant center---Birmingham---was located in a postcode area that contributed an excess of listings at *P* \< .05 but not *P* \< .002. Among postcode areas over the study period, there was a median of 22.1 listings/100 000 population (IQR 18.8‐26.7).

![Listings for liver transplantation by postcode area. The number of listings for liver transplantation 1995‐2014 for each postcode area (n = 2736) was aggregated from the constituent postcode area and plotted against the 2011 National Census population. Confidence intervals at *P = .*05 and .002 were then generated to assess for those postcode areas contributing either more or fewer than expected listings. Those areas contributing fewer listings than expected at *P* \< .002 are marked in blue; those contributing more at *P* \< .002 are marked in red; text labels represent postcode areas. Postcode areas containing a liver transplant center (7) are plotted with a square rather than a circular marker \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJT-19-208-g003){#ajt15004-fig-0003}

3.1. There is an uneven distribution of access to liver transplant centers across the United Kingdom {#ajt15004-sec-0004}
----------------------------------------------------------------------------------------------------

When calculated across the United Kingdom, marked variation in travel time to the nearest center was evident (Figure [4](#ajt15004-fig-0004){ref-type="fig"}A). Of those 11 184 listed for transplantation, 5620 (50.3%) were resident ≥60 minutes from a liver transplant center, 1262 (11.3%) were \>119 minutes away, and 494 (4.4%) were ≥180 minutes away (Figure [4](#ajt15004-fig-0004){ref-type="fig"}B). With respect to the general population of Great Britain, as measured in the 2011 National Census (n = 6.13 × 10^7^), approximately 3.38 × 10^7^ (55.1%) people were resident ≥60 minutes from a liver transplant center, 7.65 × 10^6^(12.5%) were \>119 minutes away, and 2.49 × 10^6^(4.0%) were ≥180 minutes away (Figure [4](#ajt15004-fig-0004){ref-type="fig"}C).

![Travel time to nearest liver transplant center. A, Map of Great Britain showing the locations of current liver transplant centers (cyan circles), renal transplant centers without liver transplant capability (yellow circles), and calculated travel time to the nearest liver transplant center from each postcode district in 30‐minute intervals. B, Frequency distribution of travel time from postcode district of residence of patients listed for transplantation to the liver transplant center attended (n = 11 188). Red line denotes cumulative frequency. C, Frequency distribution of travel time from postcode district of residence of total resident population to the nearest liver transplant center (n = 6.13 × 10^7^). Red line denotes cumulative frequency \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJT-19-208-g004){#ajt15004-fig-0004}

To assess whether there was a correlation between mortality from liver disease with travel time to nearest liver transplant center, we plotted ASMR for each postcode district against travel time. This revealed a negative correlation −3.51 ASMR points per 100 minutes of travel time (95% confidence interval \[CI\] to −2.97 to −4.04; *P* \< .001; *r* ^2^ = 0.061; Figures [S4](#ajt15004-sup-0004){ref-type="supplementary-material"} and [S5](#ajt15004-sup-0005){ref-type="supplementary-material"}).

To simultaneously consider both population density and travel time to the nearest transplant center, we calculated the product of the resident population of each postcode district and the travel time to the nearest transplant center (Figure [S6](#ajt15004-sup-0006){ref-type="supplementary-material"}). The largest values of "person minutes" generated related to southwest England, south Wales, and around urban centers in northern England. We then repeated this procedure but adjusted values according to the ASMR for that postcode district normalized to the average ASMR nationwide (Figure [S7](#ajt15004-sup-0007){ref-type="supplementary-material"}). After this adjustment, the largest values of "person minutes" were evident in the northwest of England.

3.2. Travel time is significantly correlated with worsened outcome from the point of listing for liver transplantation and a lower likelihood of receiving a liver transplant {#ajt15004-sec-0005}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To assess outcome after listing of transplant patients, we first divided patients into 3 groups: \<60 minutes, 60‐119 minutes, and \>119 minutes travel time to the center used. Of the 11 184 patients listed, 8865 were transplanted or removed because of an improvement in their condition, 2228 had died or were removed because of deterioration in their condition, and 95 were still active on the transplant list. Median follow‐up from listing was 75 days (IQR 26‐179 days). Of those who died or were delisted for worsening, median time to event was 96 days (IQR 34‐227 days).

The results of univariable analyses comparing average travel times across a range of factors are presented in Tables [1](#ajt15004-tbl-0001){ref-type="table"} and [2](#ajt15004-tbl-0002){ref-type="table"}. Within the cohort of listed patients, travel times were found to differ significantly by ethnicity (*P* \< .001), being longest in white patients; by blood group (*P* \< .001), being shortest for group B potential recipients; and by liver disease, being shortest in viral hepatitis. Serum bilirubin was also found to increase significantly with travel time (*P* = .012), and travel time increased over the study period (*P* \< .001), with a significant difference in travel time between transplant units (*P* \< .001).

###### 

Study population characteristics

  Variable                    Category         Listed patients   Transplanted patients                                        
  --------------------------- ---------------- ----------------- ----------------------- --------------- ------ ------------- ------------
  Age (years)                 ≤40 y            1733              64 (40‐100)             .151            1296   63 (40‐100)   .156
  \>40 ≤ 55 y                 4725             64 (38‐97)        3593                    63 (37‐97)                           
  \>55 y                      4722             65 (39‐101)       3520                    65 (38‐101)                          
  Sex                         Male             7011              64 (38‐100)             .289            5298   63 (37‐100)   .333
  Female                      4168             65 (39‐98)        3110                    65 (39‐99)                           
  BMI (kg/m^2^)               \<25             4517              65 (39‐100)             .795            3349   65 (39‐100)   .838
  ≥25 \< 30                   3539             64 (37‐102)       2760                    63 (37‐102)                          
  ≥30                         2493             65 (40‐100)       1818                    65 (40‐100)                          
  Recipient ethnicity         White            9810              68 (41‐103)             **\<.001**      7417   67 (41‐103)   **\<.001**
  Asian                       961              45 (26‐65)        711                     45 (26‐65)                           
  Black                       271              35 (19‐57)        194                     34 (18‐55)                           
  Other/mixed                 132              35 (15‐59)        86                      32 (12‐56)                           
  Serum bilirubin (µmol/L)    ≤30              2347              64 (37‐100)             **.012**        1668   65 (37‐100)   **.043**
  \>30 ≤ 60                   2025             66 (41‐100)       1501                    65 (40‐98)                           
  \>60                        2834             66 (42‐100)       1993                    65 (42‐101)                          
  Serum sodium (mmol/L)       ≤135             2741              67 (41‐100)             .407            1885   66 (40‐100)   .707
  \>135 ≤ 140                 3285             64 (40‐98)        2400                    64 (40‐98)                           
  \>140                       1163             65 (40‐105)       864                     65 (40‐105)                          
  INR                         ≤1.2             2663              66 (40‐105)             .112            1910   67 (40‐105)   .077
  \>1.2 ≤ 1.6                 2991             65 (40‐98)        2167                    65 (40‐98)                           
  \>1.6                       1512             64 (41‐95)        1056                    64 (40‐95)                           
  Serum creatinine (µmol/L)   ≤60              1295              63 (39‐101)             .138            945    63 (38‐100)   .261
  \>60 ≤ 90                   3418             65 (40‐100)       2589                    65 (40‐100)                          
  \>90                        2475             66 (41‐100)       1615                    66 (40‐100)                          
  Blood group                 O                5086              65 (39‐100)             **\<.001**      3567   64 (38‐100)   **.001**
  A                           4321             66 (40‐102)       3520                    65 (39‐100)                          
  B                           1325             55 (34‐90)        944                     56 (34‐93)                           
  AB                          448              63 (36‐92)        378                     65 (36‐94)                           
  Diabetes mellitus           No               9937              64 (38‐99)              .203            7531   64 (38‐100)   .425
  Yes                         1243             65 (40‐101)       878                     65 (39‐100)                          
  Hemodialysis                No               11056             64 (39‐100)             .414            8350   64 (38‐100)   .885
  Yes                         124              60 (37‐89)        59                      63 (38‐98)                           
  Liver disease               PBC              1376              66 (42‐102)             **\<.001**      1162   66 (41‐102)   **\<.001**
  AIH                         494              70 (42‐102)       386                     68 (42‐100)                          
  HBV                         436              47 (25‐84)        352                     47 (24.5‐84)                         
  PSC                         1027             65 (41‐101)       854                     66 (41‐102)                          
  Other                       1749             65 (40‐105)       1100                    65 (38.5‐104)                        
  Alcohol                     2920             65 (38‐98)        2172                    63 (38‐99)                           
  HCV                         1868             61 (35‐94)        1454                    60 (35‐95)                           
  NAFLD                       428              66 (45‐99)        288                     67 (46‐98)                           
  HCC                         No               9797              65 (39‐99)              .551            7324   64 (38‐99)    .524
  Yes                         1383             63 (36‐104)       1085                    63 (36‐100)                          
  Transplant unit             King's College   2148              63 (37‐108)             **\<.001**      1585   62 (36‐108)   **\<.001**
  Leeds                       1866             61 (39‐78)        1312                    58 (39‐78)                           
  Birmingham                  2723             93 (47‐123)       2095                    93 (49‐123)                          
  Edinburgh                   1196             67 (50‐96)        920                     66 (49‐94)                           
  Cambridge                   1359             75 (52‐96)        1074                    75 (52‐95)                           
  Royal Free                  1188             44 (31‐62)        894                     44 (31‐61)                           
  Newcastle                   700              32 (20‐54)        529                     32 (20‐55)                           
  Listing year                1995‐1999        2053              59 (33‐99)              **\<.001**      1708   60 (34‐99)    **.003**
  2000‐2004                   2396             65 (39‐98)        1963                    65 (39‐99)                           
  2005‐2009                   2833             65 (40‐97)        2000                    64 (39‐97)                           
  2010‐2014                   3898             65 (40‐101)       2738                    65 (40‐101)                          

AIH, autoimmune hepatitis; BMI, body mass index; INR, international normalized ratio; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IQR, interquartile range; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.

Values represent the median travel time for that category. The Mann‐Whitney test was used to compare travel times between 2 categorical variables; the Kruskal‐Wallis test was used to compare 3 or more categorical values; the nptrend test was used to test for trend across numerical values between tertiles. Blood results are from the point of listing. Bold *P* values are significant at *P* \< .05.
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###### 

Additional transplant‐related patient characteristics

  Variable                   Category   n             Median (IQR) travel time (min)   *P*
  -------------------------- ---------- ------------- -------------------------------- ------------
  Donor BMI (kg/m^2^)        \<25       3843          63 (37‐96)                       **.004**
  ≥25 \< 30                  2411       64 (38‐103)                                    
  ≥30                        1183       66 (40‐102)                                    
  Donor age (y)              ≤40        2978          63 (38‐98)                       .122
  \>40 ≤ 55                  2941       63 (38‐97)                                     
  \>55                       2490       65 (39‐102)                                    
  Cold ischemic time (min)   ≤500       2792          65 (40‐101)                      **.004**
  \>500 ≤ 750                4137       64 (38‐98)                                     
  \>750                      1480       61 (34‐97)                                     
  Days in ITU (d)            1          2402          62 (38‐89)                       **\<.001**
  2 or 3                     3543       65 (38‐103)                                    
  \>3                        2175       65 (38‐109)                                    
  Transplant weekday         Sunday     1046          65 (37‐107)                      .726
  Monday                     1123       62 (36‐100)                                    
  Tuesday                    1315       65 (38‐101)                                    
  Wednesday                  1377       63 (39‐96)                                     
  Thursday                   1233       64 (38‐100)                                    
  Friday                     1199       63 (39‐95)                                     
  Saturday                   1116       65 (41‐98)                                     
  CMV status                 D−R−       1447          68 (43‐105)                      **\<.001**
  D−R+                       2263       59 (35‐93)                                     
  D+ R+                      2280       61 (35‐100)                                    
  D+ R−                      1399       69 (44‐103)                                    
  Donor sex                  Male       4488          66 (39‐102)                      **\<.001**
  Female                     3921       62 (37‐95)                                     
  Donor ethnicity            White      6914          65 (39‐100)                      **.022**
  Asian                      138        50 (31‐85)                                     
  Black                      85         60 (37‐90)                                     
  Other/mixed                70         59 (35‐84)                                     
  Graft type                 DBD        7467          64 (38‐100)                      .645
  DCD                        941        65 (39‐100)                                    

BMI, body mass index; CMV, cytomegalovirus; D, donor; DBD, donation after brain death; DCD, donation after cardiac death; ITU, intensive treatment unit; IQR, interquartile range; R, recipient.

Values either represent the median of the characteristic concerned or the median travel time for that category. The Mann‐Whitney test was used to compare travel times between 2 categorical variables; the Kruskal‐Wallis test was used to compare 3 or more categorical values; the nptrend test was used to test for trend across numerical values between tertiles. Bold *P* values are significant at *P* \< .05.
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An unadjusted analysis of postlisting survival demonstrated significant differences between travel‐time categories (Figure [5](#ajt15004-fig-0005){ref-type="fig"}A; *P = .*003 by log‐rank test), with a hazard ratio of 1.21 (95% CI: 1.03‐1.41, *P = .*020) for the \>119 minutes vs \<60 minutes groups. However, this did not account for the rates of transplantation or recovery, which were also found to differ significantly across the groups, being lowest in the \>119 minutes group (HR: 0.91; 95% CI: 0.85‐0.96, *P = .*002, Figure [5](#ajt15004-fig-0005){ref-type="fig"}B). As such, competing risks analyses were performed, to consider both of these outcomes simultaneously. These models also accounted for other confounding factors, in order to account for the baseline differences observed between the 3 travel time groups.

![Outcome following listing for liver transplantation. A, Proportion of patients who had died following listing for liver transplantation categorized by travel time to listing transplant center (n = 11 188; *P =*.003 by log‐rank test). B, Proportion of patients who received transplantation or were removed from the waiting list because of an improvement in their clinical condition following listing for liver transplantation categorized by travel time to listing transplant center (n = 11 188; *P =*.005. by log‐rank test) \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJT-19-208-g005){#ajt15004-fig-0005}

When considering death as the primary outcome (Table [3](#ajt15004-tbl-0003){ref-type="table"}), the model found survival to be shorter in those with longer travel times (*P* \< .001), with subdistribution hazard ratios (sHRs) of 1.33 (95% CI: 1.12‐1.57, *P = .*001) for the 60‐119‐minute group, and 1.27 (1.01‐1.59, *P = .*037) for the \>119‐minute group, relative to the \<60‐minute group. When the competing risks model was reanalyzed with travel time as a continuous variable, there was a significant correlation with a greater risk of mortality with increasing travel time to transplanting center: sHR 1.09 (per 60 minutes, 95% CI: 1.02‐1.17, *P = .*013).

###### 

Risk of death from the point of listing for liver transplantation

  Variable                         sHR (95% CI)       *P*
  -------------------------------- ------------------ ------------
  Travel time tertiles             **---**            **\<.001**
  \<60 min                         1.00               ---
  60‐119 min                       1.33 (1.12‐1.57)   **.001**
  \>119 min                        1.27 (1.01‐1.59)   **.037**
  Age (/10 y)                      1.24 (1.15‐1.34)   **\<.001**
  Serum bilirubin (/100 µmol/L)    1.23 (1.17‐1.30)   **\<.001**
  Serum sodium (/10 mmol/L)        0.55 (0.48‐0.64)   **\<.001**
  Serum creatinine (/100 µmol/L)   1.25 (1.15‐1.36)   **\<.001**
  INR (per 2‐fold increase)        2.09 (1.60‐2.74)   **\<.001**
  Transplant center                ---                **.002**
  King's College                   1.00               **---**
  Leeds                            0.95 (0.74‐1.23)   .705
  Birmingham                       0.89 (0.71‐1.12)   .328
  Edinburgh                        0.90 (0.69‐1.17)   .432
  Cambridge                        0.57 (0.42‐0.77)   **\<.001**
  Royal Free                       0.91 (0.69‐1.22)   .532
  Newcastle                        0.56 (0.37‐0.84)   **.006**
  HCC                              ---                **---**
  No                               1.00               **‐**
  Yes                              0.35 (0.25‐0.48)   **\<.001**
  Blood group                      ---                **\<.001**
  O                                1.00               **---**
  A                                0.63 (0.53‐0.75)   **\<.001**
  B                                1.20 (0.96‐1.49)   .102
  AB                               0.56 (0.36‐0.89)   **.015**
  Primary liver disease            ---                **\<.001**
  PBC                              1.00               **---**
  AIH                              0.95 (0.62‐1.45)   .803
  HBV                              0.84 (0.48‐1.47)   .543
  PSC                              0.62 (0.43‐0.90)   **.012**
  Other                            1.69 (1.27‐2.25)   **\<.001**
  Alcohol                          0.94 (0.71‐1.23)   .642
  HCV                              1.03 (0.76‐1.41)   .835
  NAFLD                            1.22 (0.85‐1.74)   .275
  Ethnic group                     ---                .150
  White                            1.00               **---**
  Asian                            0.71 (0.51‐0.98)   **.038**
  Black                            0.99 (0.59‐1.66)   .965
  Other/mixed                      1.33 (0.64‐2.77)   .447

AIH, autoimmune hepatitis; BMI, body mass index; CI, confidence interval; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.

Variables presented represent those from Table [1](#ajt15004-tbl-0001){ref-type="table"} retained in the competing risks model after backwards stepwise selection: covariables excluded because of the absence of a significant effect on outcome were: sex, BMI, INR, diabetes mellitus, hemodialysis, and listing year. Subdistribution hazard ratios (sHR) are presented along with upper and lower 95% CI. Only listings with complete data are included (n = 6744). The sHR calculated for INR and days in intensive treatment unit relates to an increase of 1 in the log~2~‐transformed variable (eg, a 2‐fold increase in INR). For the other continuous factors, sHRs are for increases of the stated number of units. Blood results are from the point of listing. Bold *P*values are significant at *P* \< .05.
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A similar competing risks model to the one described above was constructed but with attaining transplantation or recovering to the point of no longer needing a transplant as the outcome of interest, with death or delisting for a decline in condition as a competing risk. Here there was a reduced likelihood of receiving a transplant associated with longer travel time, with sHRs of 0.94 (0.88‐0.99, *P* = .039) for the 60‐119‐minute group and 0.86 (95% CI: 0.79‐0.93, *P* \< .001) for the \>119‐minute group, relative to the \<60‐minute group (Table [S2](#ajt15004-sup-0010){ref-type="supplementary-material"}). When the model was reanalyzed with travel time as a continuous variable, there was a significant correlation with a reduced likelihood of receiving a liver transplant and increasing travel time to transplanting center: sHR 0.95 (0.93‐0.98; per 60‐minute travel time), *P* = .001.

3.3. Travel time is not significantly correlated with outcome following liver transplantation {#ajt15004-sec-0006}
---------------------------------------------------------------------------------------------

We next looked for differences in outcome after transplantation associated with travel time by assessing regraft‐free survival between groups of travel time. Of 8490 patients transplanted, 3050 required retransplantation or died within median follow‐up of 1596 days (IQR 536‐3306 days). The results of univariable analyses between travel time categories are presented in Tables [1](#ajt15004-tbl-0001){ref-type="table"} and [2](#ajt15004-tbl-0002){ref-type="table"}, and the results were consistent with those for the cohort of listed patients, as previously described. An unadjusted analysis of survival demonstrated no significant differences between travel‐time categories (*P =*.645 by log‐rank test) (Figure [S8](#ajt15004-sup-0008){ref-type="supplementary-material"}). A multivariable Cox proportional hazards model also found no significant difference in HR according to travel time category, after accounting for other potentially confounding factors (*P =*.532, Table [4](#ajt15004-tbl-0004){ref-type="table"}), with a HR of 0.99 (95% CI: 0.82‐1.19, *P =*.886) for the \>119‐minute group vs \<60‐minute group. Consistent results were returned from sensitivity analyses where assessments for distance from transplant center or with travel time as a continuous variable were considered (data not shown).

###### 

Cox model results for retransplant‐free survival following liver transplantation

  Variable                          Hazard ratio (95% CI)   *P*
  --------------------------------- ----------------------- ------------
  Travel time tertile                                       .532
  \<60 min                          1.00                    ---
  60‐119 min                        0.91 (0.79‐1.05)        .207
  \>119 min                         0.99 (0.82‐1.19)        .886
  Primary liver disease                                     **\<.001**
  PBC                               1.00                    ---
  AIH                               1.34 (0.93‐1.94)        .120
  HBV                               1.02 (0.68‐1.55)        .910
  PSC                               1.96 (1.51‐2.55)        **\<.001**
  Other                             1.39 (1.07‐1.81)        **.014**
  Alcohol                           1.29 (1.01‐1.65)        **.040**
  HCV                               1.75 (1.37‐2.24)        **\<.001**
  NAFLD                             1.66 (1.16‐2.36)        **.006**
  CMV status                                                **.015**
  Donor− Recipient−                 1.00                    ---
  Donor− Recipient+                 0.99 (0.83‐1.19)        .936
  Donor+ Recipient+                 1.21 (1.01‐1.45)        **.040**
  Donor+ Recipient−                 0.98 (0.80‐1.20)        .842
  Serum creatinine (/100 µmol/L)    1.20 (1.03‐1.40)        **.021**
  INR (per 2‐fold increase)         0.58 (0.42‐0.81)        **.001**
  Donor age (/10 y)                 1.08 (1.03‐1.13)        **\<.001**
  Transplant center                                         **.001**
  King\'s College                   1.00                    ---
  Leeds                             1.56 (1.15‐2.10)        **.004**
  Birmingham                        1.46 (1.13‐1.89)        **.004**
  Edinburgh                         1.64 (1.23‐2.19)        **.001**
  Cambridge                         1.73 (1.31‐2.30)        **\<.001**
  Royal Free                        1.40 (1.05‐1.87)        **.021**
  Newcastle                         1.52 (1.08‐2.12)        **.015**
  Cold ischemic time (/100 min)     1.06 (1.01‐1.10)        **.011**
  Days in ITU (per doubling in d)   1.35 (1.28‐1.44)        **\<.001**
  Listing year (/10 y)              0.68 (0.54‐0.86)        **.001**
  Recipient ethnicity                                       .052
  White                             1.00                    ---
  Asian                             0.91 (0.72‐1.16)        .458
  Black                             1.38 (0.94‐2.02)        .100
  Other/mixed                       0.19 (0.05‐0.77)        **.020**
  Transplant type                                           
  DBD                               1.00                    **---**
  DCD                               1.66 (1.38‐1.99)        **\<.001**

AIH, autoimmune hepatitis; BMI, body mass index; CI, confidence interval; CMV, cytomegalovirus; DBD, donation after brain death; DCD, donation after cardiac death; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; IQR, interquartile range; ITU, intensive treatment unit; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.

Variables presented represent those from Tables [1](#ajt15004-tbl-0001){ref-type="table"} and [2](#ajt15004-tbl-0002){ref-type="table"} retained in the competing risks model after backwards stepwise selection: covariables excluded because of the absence of a significant effect on outcome were: Age, sex, BMI, serum bilirubin, serum sodium, INR, diabetes mellitus, hemodialysis, HCC, donor age, cold ischemic time, days in ITU, transplant weekday, CMV status, donor sex, and donor ethnicity. Hazard ratios (HR) are presented along with upper and lower 95% confidence intervals. Only listings with complete data are included (n = 4158). The HR calculated for INR and days in ITU relates to an increase of 1 in the log~2~‐transformed variable, eg, a 2‐fold increase in INR. For the other continuous factors, HRs are for increases of the stated number of units. Blood results are from the point of listing. Bold *P*values are significant at *P* \< .05.

John Wiley & Sons, Ltd

3.4. The optimum site for an additional UK transplant center to reduce patient travel time is Bristol {#ajt15004-sec-0007}
-----------------------------------------------------------------------------------------------------

Having demonstrated a correlation between increasing travel time and worsened outcome, we modeled the effect on total travel time to the nearest liver transplant center of an additional liver center. An additional center was modeled at each of the existing UK mainland renal transplant centers without current liver transplant facilities: Bristol, Cardiff, Coventry, Glasgow, Leicester, Liverpool, St George's Hospital (London), the West London Renal and Transplant Centre ("Hammersmith," London), The Royal London Hospital, Manchester, Nottingham, Oxford, Plymouth, Portsmouth, and Sheffield (15 centers; Figure [S9](#ajt15004-sup-0009){ref-type="supplementary-material"}A). We calculated the reduction in person minutes of travel time that the introduction of a new center would produce in each of 4 scenarios: for all liver transplant patients listed 1995‐2014 after the exclusions described above (Figure [6](#ajt15004-fig-0006){ref-type="fig"}A), for all listed patients without exclusions applied (Figure [6](#ajt15004-fig-0006){ref-type="fig"}B), for the total population (Figure [6](#ajt15004-fig-0006){ref-type="fig"}C), and for the total population with adjustment for ASMR (Figure [6](#ajt15004-fig-0006){ref-type="fig"}D). In each case, the greatest overall reduction in patient travel time was achieved by modeling the addition of a new center in Bristol. For liver transplant listings after exclusions, a predicted saving of 82 913 minutes (10.1%) was predicted with a center in Bristol, with other centers ranging from 72 603 minutes (8.8%) with Cardiff to 10 063 minutes with Leicester (1.2%); analyses using different inclusion criteria returned consistent results. A map showing the effects of a new center at Bristol is shown as Figure [S9](#ajt15004-sup-0009){ref-type="supplementary-material"}B.

![Modeled reductions in travel time by introduction of a new liver transplant center at various locations. The models described elsewhere in this document were repeated with the addition of a hypothetical new liver transplant center at each of 15 locations. The reduction in the number of minutes of traveling time for each listing for transplantation, or member of the population, to attend their nearest liver transplant center with and without the modeled new center was calculated. Panel A represents all listings for liver transplantation 1995‐2014 after the application of our exclusion criteria; Panel B represents all listings without exclusions; Panel C represents travel for the population of England, Scotland, and Wales as at the 2011 National Census; Panel D represents the same Census population but normalized to age‐adjusted standardized mortality rates (ASMR)](AJT-19-208-g006){#ajt15004-fig-0006}

4. DISCUSSION {#ajt15004-sec-0008}
=============

Here we show that there is a significant disparity in travel time to liver transplant services across the United Kingdom. For those listed for transplantation, greater travel time to transplant center correlates with a worse outcome: a greater likelihood of death while listed and a lower likelihood of receiving a transplant. However, in contrast to reports from the United States, there was no apparent difference in outcome after transplantation for those living further from liver transplant centers.

We show that approximately 7.5 million people (around 12.5% of the population) live \>2 hours travel from a liver transplant center in the United Kingdom. There are variations in disease pathogenesis with geography, with fewer people distant from a transplant center being listed for both hepatitis B‐ and C‐related disease, perhaps reflecting the urban concentration of hepatitis and associations with ethnic grouping and relative wealth. Patients are also traveling further with time. A number of other factors including both recipient and donor ethnicity, donor sex blood groups, cytomegalovirus status, serum bilirubin, time spent in intensive treatment unit, and cold ischemic time varied significantly by distance. The first 4 of these might reasonably be explained by variations in the populations using the individual transplant centers, while the causes of variations in the last 3 are less apparent. A trend to higher bilirubin in those traveling further may be consistent with delays in referral for transplantation,[20](#ajt15004-bib-0020){ref-type="ref"} but this study lacks details of the denominator population that would be required to fully explore this. Interestingly, cold ischemic time was lower for those living further away from transplant centers. One possible explanation for this finding is patients living nearby being called in rapidly as second‐choice candidate after a problem with the first choice.

Our findings of a significant correlation between travel time to transplant center and worsened outcome after listing are consistent with the findings of 2 large US studies,[5](#ajt15004-bib-0005){ref-type="ref"}, [6](#ajt15004-bib-0006){ref-type="ref"} but not all analyses of the US system.[20](#ajt15004-bib-0020){ref-type="ref"}, [21](#ajt15004-bib-0021){ref-type="ref"} This study is not designed to explain why such variations in outcome may occur, but potential explanations include less frequent pretransplant follow‐up or less specialized pretransplant care, delays in referral for transplantation not reflected in the covariables that we have, or an unmeasured preference for offering organs to those geographically closer. Such differences warrant further examination and provide impetus to efforts to reduce such disparities in access to liver transplantation. In addition, we cannot account for possible regional variations in the approach to listing or delisting patients. Indeed, differences in the general behavior of clinicians and/or patients further from transplant centers may also explain some of the variation in outcome we describe. Such variation might be amenable to educational approaches. However, major differences in behavior might also be expected to have effects on posttransplant outcomes, and these were not evident in this study.

In contrast to work from the United States, we do not, however, show variations in outcome after transplantation in those living further from their transplanting center. One possible reason is that the geography of the United Kingdom means that the most distant patients are still nearer a transplant center than their counterparts in the United States. However, in the analysis by Goldberg et al, differences in outcome were apparent when comparing 0‐100 and 100‐200 miles of distance. Such distances are within those seen in the United Kingdom. In addition, the correlation of rurality or socioeconomic status and travel time from liver transplant center may differ between the United States and the United Kingdom and are not addressed in our study.

A further consideration is the different organization of the UK and US healthcare systems: The NHS represents a single system with a semiformalized referral network,[22](#ajt15004-bib-0022){ref-type="ref"} whereas multiple providers and funders contribute to the United Network for Organ Sharing network. Similar analyses of the effect of travel time and distance are not available for other liver transplant systems---either centralized or more diffuse.

Having demonstrated a correlation between greater travel time to transplant center and worsened outcome, we continued to model where a new liver transplant center might optimally be placed. We also note that patient preference, the logistics of organ procurement, and potential benefits to referral networks and pre/posttransplant care are also potential reasons for wishing to minimize distance between patients and transplant center, but are not examined here. Our finding of the optimal site for a new liver transplant center differs from that expected by a simple inspection of distribution of the frequency of severe liver disease as measured by ASMR: In the United Kingdom, mortality rates from liver disease are greatest in the northwest of England. The finding that ≈25% of patients listed for liver transplantation are seen in a center that is not their geographically closest suggests that factors other than travel time are also important: possibilities include physician referral patterns,[22](#ajt15004-bib-0022){ref-type="ref"} change of residence after initial referral, and differences in specialties between centers including for rarer causes.

Although our data set is relatively large with excess of 11 000 listings considered, one potential concern is that with the multiple variables examined, an otherwise statistically significant outcome signal from travel time posttransplantation might be lost. This is made less likely by significant differences in HRs for posttransplant outcome in risk factors in other studies (eg, increased mortality in those receiving organs from deceased after cardiac death donors, those receiving grafts from older donors or with longer cold ischemic times, and those with renal failure at listing).[23](#ajt15004-bib-0023){ref-type="ref"}, [24](#ajt15004-bib-0024){ref-type="ref"}

Weaknesses of this analysis include the moderate imprecision introduced by only using the first part of the postal code, although this was necessary to preserve relative anonymity, and these factors represent potential confounders of our findings. This imprecision also precludes estimates of social status and income based on place of residence, although we note that population rates of mortality from liver disease tend to be lower with greater travel time. Importantly, we only considered those who reached the point of listing for transplantation and are therefore unable to account for geographic variations in ability to access assessment for possible liver transplantation. We have, however, attempted to account for this in our geographic analysis by using ASMR as a proxy for total liver disease. It is notable, however, that a large proportion of liver‐related death in the United Kingdom is alcohol related and that these patients are often not referred for consideration of transplantation.[12](#ajt15004-bib-0012){ref-type="ref"} In addition, we only considered mortality and a requirement for retransplantation as outcomes; it is possible that patient experience, loss of productive work, financial cost, and other variables are affected by distance from transplant center. We were also unable to ascertain which patients changed their address; patient migration for the purposes of transplantation is reportedly common in the United States.[25](#ajt15004-bib-0025){ref-type="ref"} We recorded variation in outcome between centers in the United Kingdom both from the point of listing and from the point of transplantation. However, for the reasons explored above and because of the lack of information about the denominator population including those who are not accepted for listing, further work would be necessary to understand this variation. Finally, in our modeling we do not consider the addition of more than one center to the current network.

The issue of how best to approach the provision of liver transplantation in the United Kingdom is challenging. We highlight disparity in access to liver transplant centers and demonstrate a correlation between greater distance from transplant center and outcome from the point of listing for transplantation, although we do not prove causation. Further careful analysis will be required to guide future decisions on both the number and geographical distribution of liver transplant centers, including the consideration of factors other than simple mortality and chance of attaining transplantation.
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